MedDataX Logo

Natural History of Patients With PH3 and a History of Stone Events

NCT ID: NCT04542590

Last Updated: 2024-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

7 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-09

Study Completion Date

2024-07-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a natural history study of adults, adolescents, and children (starting at birth) with genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events during the last 3 years and/or the presence of pre existing stones detected by renal ultrasound at screening.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The relationship between the level of Uox and the incidence of kidney stones and/or nephrocalcinosis in patients with PH3 has not been established. The goal of this study is to record 24-hour Uox levels and the incidence of new stone formation and/or the degree of nephrocalcinosis in patients with PH3 over time.

Potential participants are screened over an up-to-7 week period according to the eligibility criteria and will then be followed every 6 months over an up-to-2-year period to determine the annualized new stone formation rate (number of new stones being formed per year) and the change in the degree of nephrocalcinosis (if applicable).

New stone formation is defined as occurrence of any of the following:

* Spontaneous stone passage in the absence of pre-existing stones
* Stone passage occurring without change in the number of pre-existing stones detected by renal ultrasound
* Appearance of new stones on renal ultrasound or 100% or more growth of a pre-existing stone (estimated area)
* Surgical removal of newly formed stones Note: Spontaneous passage or surgical removal of pre-existing stones does not meet the criteria for new stone formation.

This is a non-interventional study that will last up to 2 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hyperoxaluria Type 3

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Genetically confirmed PH3
* For participants at least 2 years of age, history of stone events (defined as presence of calcifications in the urinary tract and/or kidney, their relative location, and the number and size of stones) during the last 3 years and/or presence of pre-existing stones detected by renal ultrasound at Screening
* Uox ≥ 0.7 mmol/24 hours (adjusted per 1.73 m2 BSA in participants \< 18 years of age) OR if not able to collect 24-hour urine, average spot Uox to creatinine ratio at Screening above the 95th percentile for age:

* \> 220 mmol/mol in participants \< 6 months
* \> 170 mmol/mol in participants from 6 months to \< 12 months
* \> 130 mmol/mol in participants 12 months to \< 2 years
* \> 100 mmol/mol in participants from 2 to \< 3 years and
* \> 80 mmol/mol in participants from 3 to 5 years
* eGFR at Screening ≥ 30 mL/min or for infants aged less than 12 months, serum creatinine below the 97th percentile of a healthy population

Exclusion Criteria

* Prior or planned liver transplant within study period
* Currently receiving dialysis or anticipating dialysis during study period
* Unwillingness to comply with study procedures
Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Verity Rawson

Role: STUDY_DIRECTOR

Dicerna, A Novo Nordisk Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clinical Trial Site

Boston, Massachusetts, United States

Site Status

Clinical Trial Site

New York, New York, United States

Site Status

Clinical Trial Site

Toronto, Ontario, Canada

Site Status

Clinical Trial Site

Heidelberg, , Germany

Site Status

Clinical Trial Site

Warsaw, , Poland

Site Status

Clinical Trial Site

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Germany Poland United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DCR-PHXC-502

Identifier Type: -

Identifier Source: org_study_id